Law360, Washington (December 6, 2011, 6:42 PM EST) -- KV Pharmaceutical Co. agreed Tuesday to pay $17 million to resolve a former subsidiary's role in a long-running False Claims Act qui tam action alleging it wrongly reported to Medicaid and Medicare programs that two drugs were qualified for coverage under the federal health care systems.
St. Louis-based KV was the parent company of now-defunct Ethex Corp., which allegedly filed the false reports for nitroglycerin extended-release capsules and hyoscyamine sulfate extended-release capsules, law enforcement officials said Tuesday.
“Today’s settlement underscores our commitment to pursuing pharmaceutical companies...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.